Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects

UCB

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Device: Prefilled syringe (PFS)

Device: e-Device

Study type

Interventional

Funder types

Industry

Identifiers

NCT02806219

RA0132

Details and patient eligibility

About

This is a single center, open-label, Phase 1 bioequivalence (BE) study in healthy subjects designed to demonstrate the bioequivalence of a single dose of certolizumab pegol (CZP) 200mg when injected by means of a prefilled syringe (PFS, reference) or injected by means of a injection device (e-Device, test).

Enrollment

100 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Subject is male or female and between 18 and 55 years of age at Screening.
Subject is in good physical and mental health status determined on the basis of the medical history and a general clinical examination.
Subject has no evidence of active or inactive Tuberculosis (TB).
Female subjects of childbearing potential should have a negative pregnancy test at study entry and should be using a medically accepted method of contraception during the entire duration of the study and for 10 weeks after the final dose of CZP.

Female subjects who are postmenopausal for at least 2 years and have a serum follicle stimulating hormone (FSH) level >40mIU/mL at the Screening Visit, or have undergone a hysterectomy, bilateral tubal ligation, and/or bilateral ovariectomy, or have a congenital sterility are considered not of childbearing potential.

Exclusion criteria

Subject receiving any live (includes attenuated) vaccination or immunoglobulins within 56 days preceding the CZP injection.
Subject has taken any drugs (including over-the-counter medications) within 56 days preceding the CZP injection (with the exception of those noted in Section 7.8.1.).
Subject is known to be intolerant to pegol.
Subject has previously received CZP.
Subject has received TNFα-inhibitors within 12 months or other biologic within 6 months before randomization into the study.
Subject has an active or chronic/latent infection including TB, hepatitis C virus (HCV), hepatitis B core antigen (HBc), or human immunodeficiency virus (HIV).-- Subject has symptomatic herpes zoster infection (shingles) within 6 months prior to Screening.
Subject has chronic, serious, opportunistic recurring infection or condition within 6 months prior to Screening.